Format

Send to

Choose Destination
Clin Pharmacol Ther. 2010 May;87(5):539-42. doi: 10.1038/clpt.2009.227.

The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.

Author information

1
Merck, Rahway, New Jersey, USA.

Abstract

Precompetitive collaboration is a growing driver for innovation and increased productivity in biomedical science and drug development. The Biomarkers Consortium, a public-private platform for precompetitive collaboration specific to biomarkers, demonstrated that adiponectin has potential utility as a predictor of metabolic responses to peroxisome proliferator-activated receptor (PPAR) agonists in individuals with type 2 diabetes. Despite the challenges overcome by this project, the most important lesson learned is that cross-company precompetitive collaboration is a feasible robust approach to biomarker qualification.

PMID:
20407460
DOI:
10.1038/clpt.2009.227
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center